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ABSTRACT 
 
Most drugs currently entering the clinical pipeline for severe malaria therapeutics are of 
lipophilic nature, with a relatively poor solubility in plasma and large biodistribution 
volumes. Low amounts of these compounds do consequently accumulate in 
circulating Plasmodium-infected red blood cells, exhibiting limited antiparasitic activity. 
These drawbacks can in principle be satisfactorily dealt with by stably encapsulating 
drugs in targeted nanocarriers. Here this approach has been adapted for its use in 
immunocompetent mice infected by the Plasmodium yoelii 17XL lethal strain, selected 
as a model for human blood infections by Plasmodium falciparum. Using 
immunoliposomes targeted against a surface protein characteristic of the murine 
erythroid lineage, the protocol has been applied to two novel antimalarial lipophilic drug 
candidates, an aminoquinoline and an aminoalcohol. Large encapsulation yields of 
>90% were obtained using a citrate-buffered pH gradient method and the resulting 
immunoliposomes reached in vivo erythrocyte targeting and retention efficacies of 
>80%. In P. yoelii-infected mice, the immunoliposomized aminoquinoline succeeded in 
decreasing blood parasitemia from severe to uncomplicated malaria parasite densities 
(i.e. from ≥25% to ca. 5%), whereas the same amount of drug encapsulated in non-
targeted liposomes had no significant effect on parasite growth. Pharmacokinetic 
analysis indicated that this good performance was obtained with a rapid clearance of 
immunoliposomes from the circulation (blood half-life of ca. 2 h), indicating a potential 
for improvement of the proposed model. 
 
Keywords: immunoliposomes; malaria; nanomedicine; Plasmodium falciparum; 
Plasmodium yoelii 17XL; targeted drug delivery. 
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1. Introduction 
 
Malaria is one of the most devastating parasitic diseases affecting humans and a 
prominent global health concern, causing nearly half million deaths worldwide every 
year [1]. Most severe clinical manifestations, in which patients are frequently unable to 
take oral solid medications and high parasite densities are consistently found [2], are 
derived from the Plasmodium falciparum intraerythrocytic cycle [3,4]. For this reason, 
the blood stages of the pathogen have been widely considered for the development of 
several red blood cell (RBC) and/or parasitized RBC (pRBC)-targeted antimalarial 
approaches based on the use of liposomal and polymeric drug nanocarriers [5-11]. 
These strategies rely mostly on the cell-specific delivery of nanoparticle payloads in 
order to improve the shortcomings commonly associated with the pharmacokinetics 
and pharmacodynamics of current antimalarial compounds. These are mainly high 
biodistribution volumes and low effective local drug concentrations particularly in the 
case of easily metabolized and poorly water-soluble compounds [12-15], which incur 
the risk of generating resistant parasites [2,16,17]. As a consequence, the 
administration of high drug doses to the patient is required for a proper antimalarial 
effect, which results in an increased likelihood of causing toxic side effects. 
RBCs offer opportunities in drug delivery systems, either functioning as long-
circulating carriers for biologically active compounds [18] and/or providing numerous 
anchoring points for the attachment of nanoparticles [11,19,20]. Mature erythrocytes 
exhibit in this regard several attractive and exploitable features that include (i) minimal 
or absent MHC class I antigen presentation which masks this cell type from the 
immune system surveillance [21], (ii) absence of intracellular organelles along with 
minimal metabolic activity restricted to glycolysis maintenance through the Embden-
Meyerhof pathway, generation of reductive potential for protection against oxidative 
stress and oxygen/carbon dioxide transport [22], (iii) a sialic acid-rich glycocalyx which 
together with the preferential localization of negatively charged lipids in the inner 
plasma membrane of the cell [23] provides a good retention of positively ionized, 
weakly basic compounds, and (iv) a large intracellular volume of ca. 90 fL [24,25]. 
Nevertheless, the use of RBCs as carriers requires tedious processes like a prior ex 
vivo cell manipulation step (e.g. intracellular drug loading or the covalent attachment of 
functional molecules to the RBC surface) for later reinfusion into compatible receptors 
[18]. 
Erythroid-specific markers are abundant on the RBC surface and are widely 
conserved among humans [26-31] when compared to the highly polymorphic parasite 
proteins exported to the pRBC membrane [32-34], and their presence is not affected by 
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P. falciparum infection [11]. These features allow for the design of novel combinatorial 
strategies relying on both antimalarial therapy and its prophylaxis, although such 
approach has been barely explored against bloodborne infectious disease. Preliminary 
assays were conducted using passively-loaded chloroquine (CQ) into RBC-targeted 
immunoliposomes (iLPs), which resulted in significant Plasmodium berghei growth 
inhibition when compared to administration of the free compound [9]. However, only 
20% of the injected iLPs bound circulating RBCs, possibly due to poor antibody 
recognition of target cells. Other common obstacles include limitations in the 
intracellular loading of drugs due to the lack of endocytic activity taking place at the 
surface of RBCs and pRBCs [35], and little evaluation of the LP encapsulation capacity 
of drugs exhibiting distinct physicochemical properties (e.g. charge and hydrophilic vs. 
lipophilic nature). A previously proposed iLP nanocarrier targeted against human 
glycophorin A (GPA), an erythroid lineage-specific protein, has displayed the best 
[RBC+pRBC] in vitro targeting efficacies and retention yields obtained so far (~100% 
after only 15 min exposure time to cells) and provided a significant improvement in CQ 
antimalarial activity in vivo, clearing P. falciparum parasitemia to below detectable 
levels (<0.01%) in a humanized mouse malaria model after a 4-day dosage regimen of 
0.5 mg/kg [11]. Intracellular delivery of the encapsulated cargo was suggested to occur 
mainly by a sustained release process taking place at the targeted cell surface. The 
use of an active encapsulation strategy relying on the generation of a pH gradient [36-
38] offered a highly efficient encapsulation and stable retention of the weakly basic 
antimalarial compounds CQ and primaquine. 
Nevertheless, several weaknesses must be addressed before advancing this 
immunoliposomal approach into the clinical pipeline. The aforesaid outstanding 
performance of anti-GPA iLPs was evaluated in immunosuppressed mice engrafted 
with human erythrocytes in circulation, where the animals presented impaired innate 
and adaptive immune responses along with low blood parasite densities not exceeding 
1-3% parasitemia (i.e. uncomplicated malaria clinical feature) [11,39-41]. Moreover, iLP 
binding to GPA resulted in considerable cell-agglutinating events when exceeding 10 
µM lipid amounts in vitro [11], which limited the administration of large drug payloads in 
vivo. Exploring RBC-targeted therapeutics in a fully immunocompetent mouse model 
for falciparum malaria (i.e. mice infected with P. yoelii 17XL as murine-specific lethal 
strain effectively reproducing P. falciparum blood infection in humans [42]) is therefore 
a necessary step in order to properly validate antiparasitic efficacy in a severe malaria 
setting, and where the immune response of the host towards the delivered 
nanoparticles is not suppressed. Furthermore, the availability of a liposomal structure 
suitable for the encapsulation of lipophilic drugs is crucial in order to enlarge the 
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number of antimalarial agents capable of being intravenously delivered. This route of 
administration is required when handling severe malaria clinical processes, and is 
mainly limited at present to hydrophilic/amphiphilic drug formulations [2]. Finally, in 
accordance with WHO guidelines updates, CQ is no longer considered as gold 
standard for malaria therapy due to the massive worldwide appearance of Plasmodium 
resistant strains [2,17]. These considerations have prompted us to research novel drug 
derivatives capable of overcoming parasite resistance mechanisms and to explore a 
targeted method for rapid delivery to the circulating parasitized cells before the carrier 
is cleared from blood. 
 
2. Materials and methods 
 
2.1. Materials 
 
Except where otherwise indicated, reagents were purchased from Merck & Co., 
Inc. (Kenilworth, NJ, USA), and reactions were performed at room temperature (22 to 
24 °C). The lipids (all ≥99% purity according to thin layer chromatography analysis) 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000] (DSPE-PEG2000-Mal), and 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (DOPE-Rho) were 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Mouse monoclonal 
IgG2b anti-human GPA (SM3141P) and rat monoclonal IgG2b anti-mouse TER-119 
(AM31858PU-N) antibodies were purchased from Acris Antibodies GmbH (OriGene 
Company, Herford, Germany). 
Lipophilic aminoquinolines 7c and 7d, formerly found to display potent in vitro 
activity against intraerythrocytic chloroquine-sensitive and resistant P. falciparum 
parasites [13], were synthesized as heterocyclic-cinnamic conjugates maintaining a 
chloroquine backbone structure and characterized following previously reported 
methods [13,43]. The aminoalcohols BCN-01 and BCN-02, showing high in vitro and in 
vivo antiplasmodial efficacy against multidrug-resistant strains of P. falciparum and a 
murine model of P. berghei, were synthesized and chemically characterized as 
formerly described [12]. 10 mM stocks for these weakly basic compounds were 
prepared in methanol; because of their rapid aggregative properties in water-based 
solutions, non-encapsulated 7c/d and BCN-01/02 for in vivo assays were formulated in 
10% v/v chloroform/aqueous emulsion. Unless otherwise indicated, ionization relevant 
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pKa values at physiological pH and drug partition coefficients (log P) were calculated in 
silico using the Chemicalize software developed by ChemAxon Ltd [44]. 
 
2.2. Preparation of liposomes and encapsulation of drugs 
 
Liposomes (LPs) were prepared by the lipid film rehydration method [45]; the 
formulation DOPC:cholesterol:DSPE-PEG2000-Mal:DOPE-Rho, 84.5:10:5:0.5 was 
used for the encapsulation of lipophilic compounds, whereas for hydrophilic drug 
encapsulation DSPC (i.e. saturated-type phosphatidylcholine, PC) substituted for 
DOPC (i.e. unsaturated-type PC) to reduce membrane fluidity and permeability. Briefly, 
stock lipids in chloroform were mixed and dissolved in chloroform:methanol (2:1 v/v) in 
a round-bottom flask and organic solvents were subsequently removed by rotary 
evaporation under reduced pressure at 37 °C. Except where otherwise noted, the dried 
lipid film was hydrated in phosphate-buffered saline (PBS) supplemented with 10 mM 
ethylenediaminetetraacetic acid (EDTA) isotonic to Roswell Park Memorial Institute 
(RPMI) complete medium used for P. falciparum culture and containing Albumax II 
(RPMI-A, Invitrogen). Unilamellar vesicles were then obtained by 4 cycles of constant 
vortexing along with bath sonication (3 min each), followed by extrusion through 400 
nm polycarbonate membranes in an extruder device (Avanti Polar Lipids, Inc.). 
Throughout the lipid film hydration and downsizing processes, samples were 
maintained above the lipids' transition temperature. Sterility of LP samples was 
maintained by rinsing all material in 70% ethanol and working in a laminar flow hood. 
LP ζ-potential determination and dynamic light scattering size measurements were 
done after 1:30 sample dilution in either deionized water (Milli-Q® system, Millipore) or 
PBS, using a Zetasizer NanoZS90 (Malvern Ltd, Malvern, UK). Unencapsulated 
material was removed by buffer exchange in 7-kDa Zeba™ spin desalting columns 
(Thermo Fisher Scientific, Inc.) using isotonic PBS. For drug encapsulation, lipophilic 
compounds already solubilized in organic solvents were directly added into the initial 
lipid mixture (DOPC-based) at a 1:40 or 1:10 drug:lipid ratio for in vitro and in vivo 
applications, respectively, whereas hydrophilic drugs were incorporated in the lipid 
hydrating buffer upon LP formation (DSPC-based). Active encapsulation of drugs 
through citrate-based pH gradient formation (citric acid, pH 4.0/PBS, pH 7.4 as 
inner/outer aqueous phases of LP suspensions) was conducted according to previously 
established protocols [11]. When including pyranine in the lipid film hydration solution 
for tracking purposes, PBS-EDTA, pH 6.5, was used as solvent according to [5]. 
Encapsulation efficiency is expressed as the percentage of encapsulated drug relative 
to the total amount initially added to the liposomal sample. Data are represented as the 
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mean ± standard deviation of at least three independent measurements. Following 
previously established protocols [5,11], drug release from LP samples was determined 
at specific time points after removal of non-encapsulated material by ultracentrifugation 
(150,000 g, 1 h, 4 °C). For the characterization of drug release in the presence of 
RBCs, cells were removed by mild centrifugation (420 g, 5 min) before the 
ultracentrifugation step. 
 
2.3. Generation of iLPs 
 
Antibody (Ab) coupling to LPs was performed following established protocols 
[5,11]. Briefly, sulfhydryl groups were placed on Abs, either in primary amines or in 
aldehydes previously generated through sodium periodate (NaIO4) oxidation of 
carbohydrates in the Ab Fc region, using the crosslinkers N-succinimidyl S-
acetylthioacetate (SATA, Thermo Fisher Scientific, Inc.) or 3-(2-pyridyldithio)propionyl 
hydrazide (PDPH, Thermo Fisher Scientific, Inc.), respectively, for their subsequent 
conjugation to maleimide-containing LPs. Unconjugated Abs were removed by 
ultracentrifugation (150,000 g, 1 h, 4 °C) and pelleted iLPs were finally resuspended in 
isotonic PBS. Sterility was maintained throughout the coupling process by filtering all 
reagents through 0.22 μm pore size polyvinylidene difluoride filters (Millex-GV Syringe 
Filter Units, 4 mm, Millipore). Qualitative (sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis, SDS-PAGE) and quantitative (QuickStart™ Bradford Protein Assay, 
Bio-Rad) antibody coupling analysis, along with the number of bound Ab molecules per 
LP, was assessed in accordance with previously standardized methods [5,11]. A typical 
qualitative SDS-PAGE analysis is presented in Fig. S1. 
 
2.4. Quantification of drugs and fluorescent dyes in LP samples 
 
Encapsulated drugs were quantified by disrupting LPs through addition of 0.1 vol 
of 10% w/v SDS, followed by 10 min bath sonication at 60 °C. UV spectra were 
subsequently obtained from 2 µl of detergent-treated samples using an Epoch™ 
spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA) in Take3 mode. 
Drug standards for quantification were prepared in either RPMI-A (plus 10 min water 
bath sonication at 60 °C) or PBS depending on their lipophilic or hydrophilic nature, 
respectively. Empty SDS-treated LPs and drug solvents were used as blank controls 
for absorbance subtraction. Standard curves for drug quantification were finally 
obtained by linear/quadratic regression from at least 3 independent measurements. 
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For rhodamine quantification in human and mouse RBC samples incubated with 
iLPs, pelleted cells (700 g, 5 min) were taken up in RPMI-A and treated with one vol of 
4% v/v Triton X-100 in PBS for sample homogenization. Fluorescence measurements 
(DOPE-Rho, λex/em = 530/590 nm) were done in a Synergy HT Multi-Mode Microplate 
Reader (BioTek Instruments, Inc.). Known amounts of LPs diluted in the same matrix 
as the samples analyzed (i.e. RBC-containing RPMI-A and plasma obtained from 
untreated mice) were used as standards for quantification. In vitro liposome retention 
was expressed as the percentage of LPs within the RBC pellet fraction relative to the 
total amount present in the sample. Liposome blood clearance was determined by 
calculating the percentage of LPs in circulation (in RBC pellet plus plasma fractions) at 
a given time relative to the total liposome payload initially injected (i.e. 2 min post-
administration, t0). Blood biodistribution of LPs at specific post-administration times 
was determined by comparing the corresponding liposome concentrations within RBC 
pellet vs. blood plasma fractions. 
 
2.5. Assessment of the antimalarial activity of drugs preloaded into non-infected 
erythrocytes 
 
All human blood samples used for P. falciparum in vitro cultures were purchased 
from the Banc de Sang i Teixits (http://www.bancsang.net/) and irreversibly 
anonymized prior to their arrival. Blood group B human RBCs suspended at 6% 
hematocrit in RPMI-A were diluted with one vol of 2× concentrated drugs in RPMI-A 
and the mixture was incubated for 24 h at 37 °C. Drug-containing cells were 
subsequently spun down (700 g, 5 min) and taken up in fresh RPMI-A prior to the 
addition of pRBCs in order to obtain final parasitemia and hematocrit of 0.5% and 
3.3%, respectively. Non-washed cells containing full drug dosages and similarly mixed 
with pRBCs were included as positive control. Parasite growth inhibition was finally 
assessed as described below. 
    
2.6. P. falciparum in vitro culture and growth inhibition assays 
 
P. falciparum strains 3D7 (CQ-sensitive) and W2mef (CQ-resistant) were 
cultivated in blood group B human RBCs according to standard protocols [46]. 
Synchronized cultures in early ring stages (0-24 h post-invasion) were obtained by 5% 
sorbitol lysis [47]. Late-form trophozoite and schizont stages (24-36 h and 36-48 h 
post-invasion, respectively) were purified in 70% Percoll (GE Healthcare) [48]. 
Parasitemia was determined by microscopic counting of blood smears fixed briefly with 
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methanol and stained with Giemsa diluted 1:10 in Sorenson's buffer, pH 7.2, for 10 
min. For culture maintenance, parasitemia was kept below 5% late forms and 10% 
early forms by dilution with freshly washed RBCs and the medium was changed every 
1-2 days. In vitro growth inhibition assays were conducted using synchronized P. 
falciparum cultures (>95%) in early or late form stages at 4% hematocrit and 1% 
parasitemia as previously described [11]. Unless otherwise specified, one culture 
volume of 2× concentrated drug solution in RPMI-A was added to the parasitized cell 
suspension and the mixture was incubated under orbital stirring for 15 min in 2-ml Petri 
dishes. The cells were finally transferred to microcentrifuge tubes and spun down, 
replacing the medium with fresh RPMI-A. The resulting cell suspension was then 
seeded on 96-well plates and further incubated for a complete 48-h growth cycle under 
the conditions described above. For the determination of parasite growth inhibition, 
samples were diluted 1:100 in isotonic PBS, and the nuclei of pRBCs (the only 
nucleated cells present in the culture) were stained by addition of 0.1 μM Syto11 
(Thermo Fisher Scientific, Inc.) in the final mixture before proceeding to flow cytometry 
analysis. Growth inhibition in drug-treated samples was defined as the percentage 
decrease in parasitemia within the second generation of parasites relative to untreated 
control samples exhibiting complete parasite growth and multiplication. Drug IC50 
corresponds to the concentration leading to 50% parasite growth inhibition relative to 
an untreated control culture. 
 
2.7. Flow cytometry 
 
For Plasmodium growth inhibition determination and quantitative live cell 
targeting examination of LPs, samples were analyzed at 0.02% hematocrit in PBS with 
a BD LSRFortessa™ cell analyzer (Becton, Dickinson and Company, New Jersey, 
USA). Forward- and side-scatter areas (FSC-A, SSC-A) in a linear scale were used to 
gate the RBC population, and pRBCs stained with either Syto11 or Hoechst 33342 
fluorescent dyes were detected, respectively, by excitation through a 488 or 405 nm 
laser and emission collection with a 525/50 or 450/50 (Pacific Blue-A) nm bandpass 
filter in a logarithmic scale. pRBCs targeted by immunoliposomes incorporating in their 
formulation the rhodamine-conjugated lipid DOPE-Rho were detected by excitation 
through a 561 nm laser and emission collection with a 610/20 nm bandpass filter in a 
logarithmic scale (PE-YG-A). Acquisition was configured to stop after recording 20,000 
events within the RBC population. Parasitized erythrocytes in late forms were 
discerned from those in early stages by their increased Hoechst 33342 or Syto11 
signal, resulting from the presence of segmented parasites with multiple nuclei. RBC 
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agglutinates were determined after incubation with iLPs by counting those cell 
disproportion events in FSC height-area (H-A) confronted parameters, which indicated 
the presence of cell doublets as previously described in [11]. Agglutination rate (%) is 
expressed as the fraction of RBCs forming aggregates relative to the total number of 
erythrocytes present in the sample. 
 
2.8. Fluorescence microscopy 
 
For fluorescence assays with live cells of the targeting efficiency of iLPs, in vitro 
RBC suspensions (either blood group B human RBCs or BALB/c mouse RBCs 
collected in 0.2% w/v EDTA) were brought to 4% hematocrit and washed twice (700 g, 
5 min) in RPMI-A before their incubation with one volume of 2× concentrated iLP 
samples under orbital stirring. Unless otherwise indicated, after 30 min of iLP-RBC 
incubation, cells were diluted to 0.1% hematocrit in PBS supplemented with 0.75% w/v 
bovine serum albumin (PBS-BSA) and finally deposited onto Lab-Tek™ chambered 
coverglass slides (Thermo Fisher Scientific, Inc.). Microscopic analysis was done with 
an Olympus IX51 inverted system microscope equipped with an IX2-SFR X–Y stage, a 
U-TVIX-2 camera, and a fluorescence mirror unit cassette for UV/blue/green excitation 
and detection of the corresponding blue/green/red emission ranges. Phase contrast 
images were acquired simultaneously. When evaluating iLP performance in vivo in P. 
yoelii 17XL-infected mice, blood was collected at specific post-administration times in 
0.2% w/v EDTA or heparinized tubes when analyzing large (mouse facial vein) or small 
(terminal portion of animal tail) sample volumes, respectively. pRBC nuclei were 
stained with 2 µg/ml Hoechst 33342 and cells were finally diluted 1:200 v/v in PBS-BSA 
prior to fluorescence microscopy analysis as described above. 
 
2.9. Maximum tolerated dose (MTD) assay 
 
All experiments involving mice were performed in accordance with the 
corresponding relevant guidelines and regulations. The studies reported here were 
performed under protocols reviewed and approved by the Ethical Committee on 
Clinical Research from the Hospital Clínic de Barcelona (Reg. HCB/2014/0910). The 
animal care and use protocols followed adhered to the specific national and 
international guidelines specified in the Spanish Royal Decree 53/2013, which is based 
on the European regulation 2010/63/UE. Inbred BALB/c mice were individually 
monitored during 8 days following an analogous drug dosage regime to the in vivo 
assays performed in this work. In the presence of toxic effects including, among others, 
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>20% reduction in animal weight, aggressive and unexpected animal behavior or the 
presence of blood in defecations, animals were immediately anesthetized using a 100 
mg/kg Ketolar plus 5 mg/kg Midazolan mixture and sacrificed by cervical dislocation. 
Drug MTD was therefore defined upon completion of the assay as the highest dosage 
exhibiting an absence of the aforesaid toxicity signs. 
 
2.10. Determination of P. yoelii 17XL growth inhibition in mice 
 
Plasmodium growth inhibition in vivo was assessed in immunocompetent female 
BALB/c mice infected with the P. yoelii 17XL lethal strain after following daily treatment 
courses with antimalarial drugs and according to protocols previously established [37]. 
Briefly, 2-3 hours prior to starting drug treatment (day 0), healthy mice were 
intraperitoneally administered 2 × 107 parasitized erythrocytes from an already infected 
mouse. Each of 3 animal replicates per sample subsequently received daily drug 
dosages administered either intraperitoneally or intravenously (i.v.). P. yoelii 17XL-
infected mice injected with drug solvents (untreated mice) were included for 
determination of the maximum parasite replication rate. Parasitemia was monitored 
daily from day 0 by microscopic examination. Antimalarial activity of the compounds 
studied in this work is expressed in terms of daily reductions in the parasite replication 
rate as well as of the overall growth inhibition, the latter being determined the day after 
completing drug administrations and expressed as the reduction of parasitemia 
percentage in treated mice relative to control untreated animals exhibiting maximum 
parasite growth and replication. 
 
3. Results and Discussion 
 
3.1. Selection of antimalarial drugs and characterization of their interaction with RBCs 
 
Considering the major goals of this RBC-targeted immunoliposomal approach 
(transporting amphiphilic/lipophilic compounds and displaying a simultaneous 
therapeutic/prophylactic antimalarial activity), the capacity of several antimalarial drugs 
to become internalized and retained into RBCs for their later inhibition of P. falciparum 
growth was first assayed in vitro. The antiplasmodial agents studied here belong to the 
4-aminoquinoline (CQ and its derivatives 7c and 7d), 8-aminoquinoline (primaquine 
and tafenoquine), aminoalcohol (quinine, BCN-01 and BCN-02), and 9-aminoacridine 
(quinacrine) drug classes (Fig. 1). These compounds were selected on the basis of: (i) 
the presence of weakly basic groups undergoing protonation in the pH range 4.0-7.4, a 
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property which is required for active encapsulation in liposomes keeping a pH gradient; 
(ii) adequate molecular dimensions in order to avoid causing structural deformations 
when inserted into the liposome membrane; and (iii) their hydrophobic nature, feature 
represented by the octanol/water partition coefficient or log P (Table 1). 7c and 7d had 
been formerly reported to display potent in vitro activity against blood stages of CQ-
sensitive and CQ-resistant P. falciparum strains, while being unable to exhibit such 
antimalarial potency in vivo when in free form [13]. The antiplasmodial activity of 
aminoalcohols BCN-01 and BCN-02 had been validated in vitro against both CQ-
sensitive and multidrug-resistant P. falciparum strains and in vivo using the P. berghei 
murine malaria model [12], although this parasite species displays a reticulocyte-prone 
infective tropism similar to that of Plasmodium vivax human malaria, which significantly 
differs from P. falciparum pathophysiology. 
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Fig. 1. Un-ionized molecular structures of the antimalarial compounds studied in this 
work. The corresponding pKas are indicated in Table 1. 
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Table 1 
Description of the compounds assayed in this work. pKa and log P values were 
obtained from the Chemicalize software developed by ChemAxon Ltd [44], except for 
CQ [49] and primaquine [50]. pKa, pKa1/2: pKas indicated in Fig. 1, which correspond 
to groups that become ionized in the pH gradient of the liposomal system used here 
(4.0-7.4). Mr: relative molecular mass. 
Drug Family Mr Molecular formula pKa, pKa1/2 log P Solvent 
Quinine Aminoalcohol 324.42 C20H24N2O2 9.05/4.02 2.51 Methanol 
BCN-01 Aminoalcohol 477.88 C21H23F4N3O3 · HCl 9.78 3.84 Methanol 
BCN-02 Aminoalcohol 491.48 C25H25F4N3O3 9.77 4.83 Methanol 
Chloroquine 4-aminoquinoline 515.86 C18H26ClN3 · 2H3PO4 10.2/8.4 4.72 H2O 
7c 4-aminoquinoline 421.97 C25H28ClN3O 7.31 5.41 Methanol 
7d 4-aminoquinoline 409.91 C23H24ClN3O2 7.31 4.01 Methanol 
Primaquine 8-aminoquinoline 455.34 C15H21N3O · 2H3PO4 10.4/3.2 3.20 H2O 
Tafenoquine 8-aminoquinoline 581.58 C24H28F3N3O3 · C4H6O4 
10.2/3.2 4.97 Methanol 
Quinacrine 9-aminoacridine 472.88 C23H30ClN3O · 2HCl 10.33/8.37 5.15 H2O 
 
 
The antimalarial prophylactic activity of all compounds included in this work was 
assessed in a three-step process: (i) initial 24 h incubation with human RBCs to 
maximize drug partition and internalization into the cells; (ii) washing of RBCs to 
remove non-incorporated drug prior to infection with P. falciparum at two different 
metabolic stages in the intraerythrocytic parasite cycle: ring (early) and 
trophozoite/schizont (late) forms; and (iii) parasite growth finally measured after a 48 h 
replication cycle. Most antimalarials exhibited non-significant differences in their activity 
when comparing washed vs. non-washed RBCs regardless of the parasite stage (Figs. 
S2 and S3; Tables 2 and S1), which reflected their lipophilic character and thus their 
affinity for RBC plasma membranes. Significant differences were only obtained for 
quinine (compound presenting the lowest log P, 2.51 units), and the highly protonated 
antimalarial CQ (pKas 8.4 and 10.2). For subsequent encapsulation assays in targeted 
immunoliposomes, four drugs were selected on the basis of their novelty and/or high 
antimalarial activity, namely BCN-02, 7c, quinacrine and CQ. 
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Table 2 
P. falciparum growth inhibition assays in parasite cultures at either ring (early) or late 
forms. The results are expressed as parasite growth IC50 (nM) after drug 
internalization into RBCs (washed RBCs), compared to non-washed RBC samples in 
which excess of antimalarials was not removed. IC50 values were calculated 
considering the initially added drug concentrations. Included in the table are the 
corresponding washed vs. non-washed IC50 fold change rates along with their related 
p values calculated using log10(IC50) values (Table S1). NA: not analyzable. 
 IC50 (nM)   
 
Washed RBCs Non-washed RBCs Fold change p value 
 Rings 
Quinine 2303.0 438.0 5.3 3.3×10-3 
BCN-01 4393.0 3574.0 1.2 0.39 
BCN-02 508.9 334.3 1.5 0.09 
Chloroquine 162.8 50.4 3.2 1.4×10-3 
7c 5888.4 1047.1 5.6 0.73 
7d NA 3715.4 NA NA 
Primaquine NA ~10000 NA NA 
Tafenoquine 9066.0 4298.0 2.1 0.87 
Quinacrine 56.2 21.9 2.6 0.55 
     
 
Late forms 
Quinine 2350.0 478.8 4.9 0.01 
BCN-01 4307.0 2663.0 1.6 0.10 
BCN-02 454.9 350.2 1.3 0.48 
Chloroquine 162.3 17.8 9.1 0.03 
7c 1513.6 138.0 11.0 0.22 
7d 1148.2 128.8 8.9 0.35 
Primaquine NA 8511.4 NA NA 
Tafenoquine NA 3020.0 NA NA 
Quinacrine 44.7 14.5 3.1 0.26 
 
 
3.2. Analysis of the encapsulation efficiency into liposomes of the selected compounds 
 
The capacity of the selected lipophilic antimalarials BCN-02 and 7c to become 
actively encapsulated into LPs using a citrate/phosphate-buffered pH gradient system 
was determined. Because these compounds must be prepared in organic solvents and 
incorporated into the lipid mixture during LP preparation, their interaction with LPs at 
pH 4.0 and their subsequent retention upon formation of the pH gradient was first 
analyzed through a buffer exchange process. Drug-nanoparticle interaction in acidic 
conditions was evaluated by measuring LP ζ-potential (Table S2). Both BCN-02 and 7c 
induced large LP surface charge modifications when compared to the drug-free control 
LP sample due to their strong hydrophobicity of 4.8 and 5.4 log P units, respectively 
(Table 1). Furthermore, BCN-02 imparted a higher nanoparticle surface charge in 
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comparison to 7c most likely because of its more ionizable basic group (respective 
pKas of 9.8 and 7.3). Remarkably, an absence of LP surface charge alteration relative 
to drug-free LPs used in this work as negative control was observed after buffer 
exchange, indicating effective drug internalization. 
A method for the rapid UV/visible spectral quantification of LP-encapsulated 
cargo was developed to determine the amounts of the antimalarial compounds under 
study throughout the internalization process and in the presence of liposome 
components. Briefly, solutions containing LPs actively loaded with the four selected 
drugs were treated with 1% SDS and sonicated for a few minutes to disrupt LP 
particles while solubilizing drugs within detergent micelles. Neither liposome 
components nor SDS caused interferences in absorption spectra of the drugs after 
treatment (Figs. S4 and S5). In accordance with LP surface ζ-potential data, BCN-02 
was better retained than 7c after the buffer exchange step (ca. 75% vs. 60%, 
respectively, of total drug initially present in the citrate-solubilized lipid mixture; Table 
3). 
 
Table 3 
Analysis of active drug encapsulation into LPs through a citrate/phosphate-buffered pH 
gradient. Drug concentration was determined by UV/vis spectroscopy (Figs. S4 and 
S5) after each step of the process including (i) initial LP formation in citrate buffer (LPs 
citrate; here the lipophilic compounds 7c and BCN were incorporated), (ii) buffer 
exchange (BE) with PBS (LPs post-BE; here the water-soluble CQ and quinacrine were 
added to preformed LPs), and (iii) ultracentrifugation of samples in PBS (LPs post-
ultra) to determine encapsulated drug at the end of the process. The volumes of all 
samples were kept equal for a straightforward reading of drug concentrations. EE: 
encapsulation efficiency. 
 
Drug (µM), mean ± SD EE (%), mean ± SD 
BCN-02 
LPs citrate 221.3 ± 1.5 - 
LPs post-BE 165.2 ± 4.9 74.7 ± 2.2 
LPs post-ultra 169.8 ± 8.1 102.8 ± 4.9 
   
 
7c 
LPs citrate 205.5 ± 19.3  - 
LPs post-BE 121.9 ± 19.4 59.0 ± 5.3  
LPs post-ultra 107.7 ± 17.8 90.5 ± 5.4 
   
 
Chloroquine 
LPs post-BE + Drug 225.1 ± 6.0 - 
LPs post-ultra 206.3 ± 4.7 91.6 ± 2.1 
   
 
Quinacrine 
LPs post-BE + Drug 234.0 ± 1.8 - 
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LPs post-ultra 223.0 ± 3.2 95.3 ± 1.4 
 
 
All compounds were quantitatively retained with more than 90% drug remaining 
stably internalized after ultracentrifugation of phosphate buffer-exchanged LP samples. 
Remarkable retention efficiency was maintained up to 30 days in storage conditions 
(Fig. S6A). A significant increase of released drug amounts was observed under in vitro 
culture conditions, especially in the presence of RBCs (Fig. S6B,C). The lipophilic 
compounds BCN-02 and 7c exhibited the largest cumulative release yields of ca. 20-
30% after 30 min incubation in the presence of cells (Fig. S6C), presumably due to the 
existence of lipid exchange mechanisms taking place between LPs and plasma 
membranes, as theorized in previous works [5,51]. Alternatively, sustained release 
processes driven by temperature and dilution-dependent depletion of the proton 
gradient across LP membranes [11] might be hypothesized for the leak of the 
hydrophilic compounds CQ and quinacrine from LPs, which accounted for ~20% 
release yields after 6 h incubation with RBCs (Fig. S6C). Drug internalization into RBCs 
would be explained in this case by passive diffusion of released un-ionized molecules 
across lipid bilayers. 
 
3.3. Immunoliposome targeting to mouse RBCs 
 
The conjugation of LPs with the TER-119 monoclonal Ab (TER119-iLP model), 
specific for a 52 kDa RBC surface antigen characteristic of the murine erythroid lineage 
and specifically expressed from the early proerythroblast to mature RBC stages 
[52,53], was optimized in order to design a RBC-targeted nanoparticle to be used in 
immunocompetent mice. In parallel, the coupling of LPs with the monoclonal mouse 
anti-human GPA Ab (GPA-iLP model, [11]) was improved for the reduction of 
agglutinating events in vitro during the performance of Plasmodium growth inhibition 
assays. iLP generation was based on the conjugation of freshly prepared maleimide-
containing LPs with thiolated antibodies. Sulfhydryl groups were introduced through 
two distinct approaches: (i) derivatization of Ab primary amines with the SATA 
crosslinking agent was used for both anti-GPA- and TER119-iLP models with an Ab:LP 
ratio of 0.1 to 1 mg Ab/ml of 10 mM lipid (i.e. 10-100 µg Ab/µmol lipid; for simplicity, the 
Ab/lipid ratio used in iLP preparation will be hereafter expressed as µg Ab/µmol lipid). 
Different SATA:Ab molar ratios (10× to 2×) were analyzed for TER-119 conjugation in 
order to explore the potential loss in antigen recognition due to modification of primary 
amines in the vicinity of the antigen-binding site. (ii) Oriented TER-119 coupling to 
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liposomes through the carbohydrate moiety in Ab Fc regions was studied comparing 
two different degrees of carbohydrate oxidation using 10 and 5 mM NaIO4. Efficiency of 
anti-GPA and TER-119 antibody conjugation to liposomes was finally evaluated in vitro 
as the capacity of the resulting iLPs to target human and mouse erythrocytes, 
respectively. 
Using 10× SATA:Ab, small differences in the percentage of targeted cells (Fig. 
2A) and in the amount of RBC-retained GPA-iLPs (Fig. 2B) were observed above 50 
µg Ab/µmol lipid, but at lower Ab:LP ratios GPA-iLP binding efficacy to target cells 
significantly decreased, as evidenced by the fall in the fraction of retained iLPs. A 
considerable reduction in GPA-iLP-mediated RBC agglutination from more than 40% to 
~27% at 100 µM lipid was obtained when decreasing the antibody concentration during 
iLP preparation from 100 to 50 µg Ab/µmol lipid, respectively (Fig. 2A), and an absence 
of agglutinates was observed at 10 µM lipid for ≤50 µg Ab/µmol lipid (Fig. 2C). Based 
on these data, for subsequent experiments 50 µg Ab/µmol lipid and 10× SATA:Ab were 
therefore selected, which resulted in 111 ± 8 Ab molecules per LP. 
LP conjugation with TER-119 through Ab primary amines using 10× SATA:Ab 
resulted in iLPs exhibiting an almost complete RBC targeting above 10 µM lipid (Figs. 
2D and S7), albeit with most iLPs not retained onto cells even at a conjugation ratio of 
100 µg Ab/µmol lipid (Fig. 2E). The same Ab concentration but using 5× and 2× 
crosslinker amounts improved respective iLP retention yields to about 30-40% and 10-
30% and also increased cell targeting rates and minimized agglutination (Fig. 2D). This 
improvement obtained at smaller SATA:Ab molecular ratios likely reflected 
interferences in antigen recognition upon excessive TER-119 primary amine 
modification. An almost complete retention onto RBCs was achieved by means of 
increasing the incubation time from 30 min to 3 h and doubling the amount of cells 
during incubation from 2 to 4% hematocrit (Fig. S8). In comparison, conjugation of 
equal amounts of antibodies through carbohydrate moieties exhibited slightly lower 
retention capacity (≤20%; Fig. 2E) regardless of the TER-119 oxidation state. Because 
of the lack of agglutination observed up to 50 µM lipid (where a 100% RBC targeting 
was achieved) for TER-119 conjugated to liposomes using 5× SATA:Ab at 100 µg 
Ab/µmol lipid (Figs. 2D and S9), these settings (resulting in 133 ± 11 Ab molecules per 
LP) were selected for in vivo assays.  
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Fig. 2. Optimization of RBC-specific monoclonal antibody coupling to LPs. (A-C) 
Analysis of anti-GPA Ab conjugation efficacy through primary amines (using 10× 
SATA:Ab and 10 to 100 µg Ab/µmol lipid during the conjugation reaction), represented 
as percentage (A) of targeted and agglutinated human RBCs and (B) of retained LPs 
after 30 min incubation. (C) Fluorescence microscopy images of the 10 µM lipid 
samples from panel A. (D,E) Analysis of TER-119 Ab conjugation efficacy through 
either primary amines at different SATA:Ab ratios or carbohydrate moieties with 
different degrees of oxidation (5 or 10 mM NaIO4), using 50 or 100 µg Ab/µmol lipid; 
the data are represented as percentage (D) of targeted and agglutinated mouse RBCs 
and (E) of retained LPs after 30 min incubation. 
 
3.4. In vitro P. falciparum growth inhibition activity of iLP-encapsulated drugs 
 
To choose the best iLP-encapsulated drug (iLP[drug]) candidates for in vivo 
assays, the antimalarial activity of the drugs actively encapsulated in the GPA-iLP 
nanocarrier was assayed in vitro in P. falciparum cultures of the 3D7 strain. After only 
15 min incubation with parasite cultures at both early and late stages, 
immunoliposomal encapsulation provided a significant decrease in drug IC50 values 
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when compared to the same amounts administered in free form (Fig. 3). BCN-02 and 
7c offered the best improvement in growth inhibition activity upon encapsulation, with 
respective iLP[drug] vs. free drug IC50 fold change units obtained when administered 
to early/late parasitic forms of 14.8/12.8 for 7c and of 5.7/5.6 for BCN-02 (Tables 4 and 
S3). Remarkably, the GPA-iLP-encapsulated CQ structural analogue 7c (GPA-iLP[7c]) 
was even more effective against the CQ-resistant W2mef P. falciparum strain when 
administered to late forms, leading to a 26.4 IC50 fold change vs. free 7c, with an 
absolute IC50 around half that obtained with 3D7 (48.6 vs. 100.7 nM, respectively). On 
the other hand, a similar enhancement upon encapsulation of CQ antiparasitic efficacy 
was obtained in both 3D7 and W2mef, although requiring in the latter case significantly 
larger drug amounts. 
 
Fig. 3. In vitro P. falciparum growth inhibition assays. GPA-iLP-encapsulated vs. freely 
delivered antimalarials were added to parasite cultures at either ring or late stages and 
removed after 15 min; parasitemia was determined after 48 h of incubation. (A) 
Analysis of BCN-02, 7c, CQ and quinacrine with the P. falciparum 3D7 strain. (B) 
Comparative analysis of 7c and CQ added at late stages to 3D7 and to the CQ-
resistant W2mef P. falciparum strain. 
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Table 4. Analysis of the data from Fig. 3. Results are expressed as parasite growth 
IC50 (nM) and the corresponding free drug vs. GPA-iLP[drug] IC50 fold change. p 
values were calculated using log10(IC50) values (Table S3). 
 IC50 (nM)   
 
Free drug GPA-iLP[drug] Fold change p value 
 Rings (3D7) 
BCN-02 1021.0 178.6 5.7 <1 × 10-4 
7c 1230.3 83.2 14.8 <1 × 10-4 
Chloroquine 174.5 56.3 3.1 9 × 10-4 
Quinacrine 110.6 44.3 2.5 <1 × 10-4 
     
 
Late forms (3D7) 
BCN-02 1076.0 192.9 5.6 <1 × 10-4 
7c 1288.2 100.7 12.8 <1 × 10-4 
Chloroquine 174.5 51.1 3.4 1 × 10-3 
Quinacrine 103.5 44.4 2.3 <1 × 10-4 
     
 Late forms (W2mef) 
7c 1281.5 48.6 26.4 <1 × 10-4 
Chloroquine 2392.0 649.7 3.7 0.01 
 
 
3.5. MTD and pharmacokinetic analysis of 7c and BCN-02 
 
Mouse administration regimes were determined for the lipophilic compounds 7c 
and BCN-02, which displayed the highest in vitro antiparasitic activity improvements 
after their encapsulation in GPA-iLPs. The MTD for 7c had been previously established 
to be around 30 mg/kg [13]. A higher toxicity (MTD of 10 mg/kg) was obtained after 4-
day intraperitoneal administration of BCN-02 emulsified in 10% v/v chloroform/RPMI-A 
(Table S4). When intravenously delivered at ≥1 mg/kg in the same emulsification 
mixture, which when free of drug was well tolerated by mice, both compounds caused 
severe toxicity killing the animals within three days post-administration (Table S5).  
The toxicity of BCN-02 and 7c was further explored after liposomization of the 
compounds. Upon i.v. administration, passively encapsulated 7c and BCN-02 were 
remarkably well tolerated up to 10 and 20 mg/kg, respectively (Table S6). The in vivo 
pharmacokinetic behavior of both compounds encapsulated in non-targeted LPs was 
evaluated in mice after one single 10 mg/kg i.v. injection, which corresponded to an 
initial lipid concentration in blood of ~5 mM at the start of the analysis (Fig. 4A). 
Liposome circulation half-lives of about 6 h were determined in accordance with 
previous assays [11], with ~90% LPs still in circulation 90 min after administration. The 
antimalarial activity of the liposomized drugs was finally examined in P. yoelii 17XL-
infected mice following a 4-day i.v. dosage regimen, being parasitemias determined on 
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the day after completing the injections (Fig. 4B). Modest antimalarial effects below ca. 
20% decrease in blood parasite load were observed between 1 and 10 mg/kg 
administrations, but a considerable 45-55% parasitemia reduction was obtained at 20 
mg/kg for both 7c and BCN-02. 
 
 
Fig. 4. In vivo pharmacokinetic analysis of 7c and BCN-02 administered i.v. and 
passively encapsulated in non-targeted liposomes. (A) Analysis of liposome residence 
in blood for 10 mg/kg drug dosage corresponding to a ca. 5 mM lipid concentration in 
circulation at the start of the analysis. (B) 4-day antimalarial assay in P. yoelii 17XL-
infected mice after administration of 1 to 20 mg/kg liposomized drug dosages. Activity 
is expressed as the percentage of parasitemia reduction in comparison to untreated 
infected animals, determined one day after completing the administrations. 
 
3.6. Pharmacokinetic and blood biodistribution analysis of TER119-iLPs 
 
Possible effects of the different methods used for LP functionalization with TER-
119 (primary amine vs. Fc carbohydrate crosslinking procedures) and dosage 
reduction on nanocarrier blood pharmacokinetics and plasma vs. RBC biodistribution 
were evaluated during 24 h after one single i.v. administration of iLPs devoid of drug. 
At an initial non-targeted LP blood concentration corresponding to ca. 125 µM lipid, a 
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considerable reduction in circulating LPs was observed 90 min after administration 
(~60% decrease relative to initially injected dose; Fig. 5A, LPs w/o Ab), a significantly 
larger removal rate than that previously obtained with a ca. 5 mM lipid dosage (Fig. 
4A). More than 90% LP clearance from blood was completed 6 h after administration, 
with most liposomes being always localized in the plasma fraction (Fig. 5B). LP 
coupling with TER-119 moderately ameliorated the pharmacokinetic profile to about 
40% and 80% iLP blood clearance at 1.5 and 6 h post-administration, respectively, with 
no remarkable differences observed due to the Ab conjugation technique followed. 
Over 80% TER119-iLPs were localized in the RBC fraction at t0 (2 min post-
administration), an efficient targeting which was maintained throughout the whole 
analysis, especially for primary amine conjugation using the 5× SATA:Ab ratio (Fig. 
5B). 
 
Fig. 5. Analysis of the effect on pharmacokinetic parameters of the TER119-iLP 
conjugation method (primary amines using 5× SATA:Ab vs. Fc carbohydrate oxidation 
with 10 mM NaIO4). (A) Analysis of liposome residence in blood following an initial lipid 
concentration in circulation of ~125 µM. (B) Blood distribution analysis (circulating 
RBCs vs. plasma) of iLPs; non-targeted, Ab-free liposomes (LPs w/o Ab) are included 
for comparison. 
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3.7. In vivo antimalarial activity in P. yoelii 17XL-infected immunocompetent mice of 7c 
encapsulated in TER119-iLPs 
 
The in vivo performance of the mouse RBC-targeted immunoliposomal approach 
optimized above, i.e. TER-119 conjugation to LPs via primary amine crosslinking using 
5× SATA:Ab, was finally evaluated. Bearing in mind the requirement of a rapid in vivo 
performance because of the fast iLP blood clearance kinetics observed (Fig. 5A), 7c 
was selected as actively encapsulated drug cargo due to its lower ionization degree 
within the 4.0-7.4 pH range used when compared to BCN-02 (Fig. S10). The 
corresponding higher number of un-ionized drug molecules in TER119-iLPs will result 
in an increased capacity for this carrier of transferring drug to the targeted RBC/pRBC 
membrane before being cleared from blood. Additionally, a daily decreasing 5 to 1 
mg/kg intravenous dosage regimen was established to avoid an excessive membrane 
saturation of circulating RBCs that might lead to undesired agglutination events.  
BALB/c mice were initially infected with the murine malaria parasite P. yoelii 17XL 
lethal strain as immunocompetent model for human falciparum malaria, and 
parasitemias as well as the decrease in Plasmodium replication rate were followed 
daily by optical microscopy. Finally, all animals were exsanguined the day after 
completing i.v. administrations for the evaluation of the antimalarial activity of TER119-
iLPs actively encapsulating 7c (TER119-iLP[7c]). Controls included infected mice either 
untreated or treated with 7c actively encapsulated in non-targeted liposomes (LP[7c]). 
Treatment with 7c in non-liposomal form was avoided because of its previously 
observed toxic effects in vivo above 1 mg/kg i.v. dose (Table S5). According to 
microscopic counts at the end of the assay, improved inhibition of Plasmodium growth 
was mediated by TER119-iLP[7c] in comparison to LP[7c]-treated and untreated mice, 
with respective parasitemias of 5.6 ± 1.0%, 26.0 ± 3.6% and 22.0 ± 5.6% (Fig. 6A). In 
addition, whereas an average daily parasite replication rate of 7- to 8-fold units was 
observed for both untreated and LP[7c]-treated mice, TER119-iLP[7c] administration 
resulted in a reduced replication rate of <3.5-fold units (Fig. 6B). Such differences in P. 
yoelii growth were more clearly reflected in the overall parasite replication rate (% 
parasitemia at day 3 vs. day 1) with 87.0 ± 11.0% averaged decrease when comparing 
TER119-iLP[7c]-treated (4.4 ± 1.1-fold units) vs. LP[7c]-treated and untreated mice 
(36.7 ± 3.6- and 31.1 ± 7.7-fold units, respectively). 
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Fig. 6. In vivo study of the antimalarial performance of TER119-iLP[7c] (5× SATA:Ab) 
in P. yoelii 17XL-infected immunocompetent mice. (A) Microscopic daily determination 
of mice parasitemia. (B) Replication rates and growth inhibition of the parasite, the 
latter determined on day 3 post-infection by optical microscopy and flow cytometry. 
(C,D) Analysis on day 3 post-infection of LP[7c]- and TER119-iLP[7c]-treated mouse 
blood samples by (C) flow cytometry and (D) fluorescence microscopy. Pacific Blue-A 
and PE-YG channels are included in flow cytometry plots for the analysis of pRBC-
nuclear and LP-associated rhodamine fluorescence signals, respectively. 
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Remarkably, LP[7c] administration caused no detectable effect on parasite 
development, whereas a final growth inhibition of 76.8 ± 13.4% was observed by 
optical microscopy examination following TER119-iLP[7c] administration (Fig. 6B). 
Flow cytometry analysis revealed a similar growth inhibitory effect of 70.6 ± 1.7%, as 
well as a good targeting efficacy for TER119-iLP[7c], with more than 95% 
[RBCs+pRBCs] resulting positive for rhodamine-iLP binding (Figs. 6C and S11). These 
results were qualitatively validated in parallel by fluorescence microscopy (Fig. 6D). 
However, whereas fluorescence-based techniques reported an absence of agglutinates 
on the day of analysis (Figs. 6C,D, and S11), slight reductions in mice weight of as 
much as 7.1% were observed after TER119-iLP treatment (Table S7), which might be 
indicative of potential side-effects at higher drug amounts than those assayed here. 
 
4. Conclusion 
 
In this work, we have successfully moved towards the validation of a RBC-
targeted drug delivery system for severe falciparum malaria therapeutics applicable to 
several weakly basic antimalarials exhibiting distinct lipophilic and ionizable properties. 
The capacity of erythrocytes as drug carriers for novel antimalarial prophylactic 
strategies has been demonstrated by means of their efficient loading with compounds 
exhibiting poor water solubility and/or low ionization states at physiological pH. LP 
active encapsulation through the establishment of a citrate-buffered pH gradient 
allowed for the stable incorporation of hydrophobic drugs containing weakly basic 
ionizable moieties, which become principally localized into the inner LP membrane 
leaflet (Fig. 7). The aminoalcohol BCN-02 and the 4-aminoquinoline 7c were efficiently 
delivered into P. falciparum-infected RBCs upon encapsulation into erythrocyte-
targeted immunoliposomes, inhibiting parasite growth in vitro and displaying significant 
improvements in drug activity when compared to free administered drug after only a 
15-min exposure time to P. falciparum cultures. Best improvements in drug efficacy 
due to iLP-mediated delivery were furthermore obtained for the CQ analogue 7c when 
assayed in the CQ-resistant W2mef P. falciparum strain. The mechanism of action of 
heterocyclic-cinnamic conjugates to which 7c belongs has been proposed in previous 
works to be specific of Plasmodium metabolic routes. Namely, (i) impairment of the 
new permeation pathways formed by Plasmodium during its intraerythrocytic cycle and 
(ii) inhibition of β-hematin crystallization, process mediated by incorporating the CQ-
analogous 4-aminoquinoline ring [13,43]. An absence of 7c toxicity against Huh7 
human hepatoma cells was additionally reported in these works. Taken together, these 
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data suggest that 7c might be an interesting molecule for the future development of 
iLP-based antimalarial strategies. 
 
 
 
Fig 7. Citrate-buffered pH gradient systems assayed in this work for the active 
encapsulation in iLPs of hydrosoluble (CQ, quinacrine) and poorly water-soluble (7c, 
BCN-02) compounds used for in vitro and in vivo antimalarial assays. Key steps of the 
procedure include: (A,D) PC-based LP preparation containing maleimide-derivatized, 
PEGylated phospholipids in 200 mM citrate buffer, pH 4.0; (B,E) Buffer exchange of LP 
external solution to isotonic PBS, pH 7.4, containing SATA-derivatized thiolated 
antibodies; (C,F) final ultracentrifugation step to remove material not incorporated into 
iLPs. Hydrophilic drugs are added to LP samples at (B) the PBS buffer exchange step, 
whereas poorly water-soluble antimalarials are incorporated (D) in citrate solution 
during initial LP formation. (G) Summary of the main components used for iLP[drug] 
preparation. 
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Currently there is an urgent need to increase the repertoire of drugs available for 
severe malaria therapy, where intravenous administration of high drug amounts is 
usually required to rapidly clear P. falciparum infection. The RBC-targeted 
immunoliposome proposed here for lipophilic compounds fulfills these specifications, 
having a fast effect in reducing parasite levels. The antimalarial activity of this RBC-
specific approach, previously assayed in humanized immunosuppressed mice using 
CQ as drug payload [11], has been validated in an immunocompetent and lethal 
murine malaria model similar to human blood infection by P. falciparum. The 
immunoliposomized 7c compound has been capable of reducing blood parasitemia 
down to uncomplicated levels (ca. 5%), whereas control animals treated with identical 
drug amounts encapsulated in non-targeted liposomes had parasitemias around 25%, 
a parasite load comparable to that found in severe stages of P. falciparum infection. In 
addition, the cost of humanized mice used in previous studies (ca. 2000 USD/animal) 
called for a more economically affordable strategy, especially considering the limited 
resources available for malaria research. The P. yoelii 17XL murine malaria model 
offers a cost-effective alternative for the in vivo study of immunoliposome-based severe 
malaria therapies. 
Further optimization of the prototype presented here is required for progressing 
towards the clinical pipeline. Host immune responses against the injected particle that 
would result in fast drug clearance rates from circulation can be minimized using 
antibody fragments lacking the highly immunogenic Fc region and formulating 
liposomes with PEG-derivatized lipids for surface steric stabilization [54]. The iLP 
approach used here is specifically targeted towards the TER119 marker, which has 
been widely characterized and is specifically expressed from the early proerythroblast 
to mature mouse RBC stages. Although specific iLP interactions with circulating 
leucocytes are therefore not expected, the content of PEG-bearing lipids in the 
immunoliposomes used here (5%) can still be significantly increased if required to limit 
capture in the major lymphatic and blood filtering organs (spleen and liver) and uptake 
by the mononuclear phagocyte system [55]. Finally, reducing potential side effects 
derived from RBC agglutination due to the high hematocrit found in blood 
(approximately 40% v/v occupied by RBCs) can be successfully dealt with through a 
close control on the numbers of antibodies conjugated per liposome and on the amount 
of crosslinker agents used. The search for new erythrocyte surface targets displaying 
minimal agglutinating capacity should be also contemplated, especially if considering 
the encapsulation of compounds exhibiting low antimalarial efficacies in vivo [2,13], 
which will require larger liposome amounts in circulation. 
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Fig. S1. SDS-PAGE qualitative analysis of the optimized coupling to LPs of RBC-specific 
antibodies. For each Ab are shown liposome-bound (B) and unbound (U) fractions as well as the 
original (pre-LP) Ab fraction used (all lanes contain 2 µg protein). (A) GPA-iLP conjugation using 
10× SATA:Ab and 50 µg Ab/µmol lipid. (B) TER119-iLP conjugation using 5× SATA:Ab and 100 µg 
Ab/µmol lipid. Respective anti-GPA and TER119 Ab conjugation efficiencies of 67.3 ± 4.6% and 
39.6 ± 3.2% were quantitatively determined as described in Materials and methods. The 
ﬂuorescence emission of the rhodamine-conjugated lipid (DOPE-Rho) is included as control for LP-
containing fractions.  
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Fig. S2. Analysis of the prophylactic performance of antimalarials pre-loaded in RBCs prior to 
infection with pRBCs containing P. falciparum parasites at the ring (early) stage. The results are 
expressed as parasite growth inhibition rates relative to an untreated culture (100% growth). 
Washed and non-washed conditions refer, respectively, to samples where drug which did not enter 
RBCs was either removed or left in the cultures until the end of the assay. Drug concentrations 
refer to those initially added at the start of the assays. 
 
4 
 
 
Fig. S3. Analysis of the prophylactic performance of antimalarials pre-loaded in RBCs prior to 
infection with pRBCs containing P. falciparum parasites at late stages. The results are expressed 
as parasite growth inhibition rates relative to an untreated culture (100% growth). Washed and 
non-washed conditions refer, respectively, to samples where drug which did not enter RBCs was 
either removed or left in the cultures until the end of the assay. Drug concentrations refer to those 
initially added at the start of the assays. 
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Fig. S4. UV/visible absorption spectra for the quantification of actively encapsulated drugs into 
LPs. Whole (200- to 700-nanometer wavelength range) as well as drug-selected spectra (arbitrary 
units, a.u.) were retrieved at the end of the encapsulation process for all LP[drug] samples after 
SDS-digestion and sonication as detailed in Materials and methods. Spectra from RPMI-dissolved 
free drug standards (50-500 µM concentration range) were analyzed for calibration curve 
determination. Specific wavelengths used for calibration of each drug are indicated. 
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Fig. S5. Linear and quadratic calibration curves derived from the spectral data in Fig. S4, and used 
for drug quantification after active encapsulation in LPs. RPMI buffer absorption at the respective 
drug-specific wavelengths was taken as absorbance subtraction blank. 
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Fig. S6. Analysis of the stability of liposomal preparations actively encapsulating antimalarial 
drugs. Percentual cumulative drug release under (A) storage conditions (PBS, 4 °C, 10 mM lipid) 
and (B,C) in vitro culture conditions (RPMI-A, 37 °C, 2 mM lipid) in (B) the absence or (C) presence 
of red blood cells at 10% hematocrit (50 µM encapsulated drug along with 2 mM lipid during 
incubation, corresponding to the highest [drug]/hematocrit ratio used in P. falciparum growth 
inhibition assays).    
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Fig. S7. Flow cytometry results from optimization experiments for GPA- and TER119-iLP targeting 
performance towards erythrocyte suspensions in vitro. (A) Selection of the RBC population and 
determination of RBC agglutinates (% of total cells, FSC-H vs. FSC-A confronted channels) as 
described in Materials and methods. (B) Retrieved plots for rhodamine-labeled iLP targeting 
analysis (rhodamine signal detected in PE-YG channel). RBCs alone and non-targeted LPs are 
included as negative controls. 
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Fig. S8. Improvement in mouse RBC retention in vitro efficacy of 5× SATA:Ab TER119-iLPs using 
larger hematocrits and longer incubation times. Non-targeted LPs are included as negative control. 
Results were obtained by rhodamine fluorescence quantification and are expressed as % of cell-
bound LPs relative to the total number of LPs (20 µM total lipid concentration) ± standard deviation 
for at least three independent measurements. 
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Fig. S9. Fluorescence microscopy targeting results for the improved 5× SATA:Ab TER119-iLP 
model assayed in vitro in mouse RBC suspensions. LP surface/contents are shown by 
rhodamine/pyranine fluorescence emission at different total lipid concentrations after 30 min 
incubation. Non-targeted LPs (LPs w/o Ab) are included as negative targeting control sample. 
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Fig. S10. Ionization molecular species found in solution as a function of pH for 7c and BCN-02. 
Abundances were calculated using the drug pKa values from Table 1. 
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Fig. S11. In vivo study of the antimalarial performance of TER119-iLP[7c] (5× SATA:Ab) in P. yoelii 
17XL-infected immunocompetent mice. The summary of flow cytometry data shows RBC 
agglutinating and targeting results obtained for untreated, LP[7c]-treated, and TER119-iLP[7c]-
treated mouse blood samples on day 3 post-infection. Pacific Blue-A and PE-YG channels are 
included for the analysis of pRBC nuclei (Hoechst 33342) and LP-associated (rhodamine) 
fluorescence signals, respectively. RBC agglutinates (%) from total cells in suspension were 
determined by FSC-H vs. FSC-A confronted channels as detailed in Materials and methods.  
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Table S1. Determination of statistical differences from the P. falciparum growth inhibition assays in 
Figs. S2 and S3. Parasite growth is expressed as log10(IC50, nM) ± standard deviation from at 
least three experimental replicates. Impaired t-test p values are included in the table comparing 
log10(IC50, nM) results from washed vs. non-washed RBC culture conditions. NA: not analyzable. 
 
 log10(IC50, nM) ± SD  
 
Washed RBCs Non-washed RBCs p value 
Rings 
Quinine 3.36 ± 0.15 2.64 ± 0.13 3.3×10-3 
BCN-01 3.64 ± 0.13 3.55 ± 0.09 0.39 
BCN-02 2.71 ± 0.06 2.52 ± 0.13 0.09 
Chloroquine 2.21 ± 0.09 1.70 ± 0.07 1.4×10-3 
7c 3.70 ± 2.45 3.02 ± 2.00 0.73 
7d NA 3.33 ± 0.79 NA 
Primaquine NA ~3.71 NA 
Tafenoquine 3.96 ± 1.91 3.63 ± 2.48 0.87 
Quinacrine 1.71 ± 1.07 1.28 ± 0.43 0.55 
    
 
Late forms 
Quinine 3.37 ± 0.18 2.68 ± 0.14 0.01 
BCN-01 3.63 ± 0.09 3.42 ± 0.15 0.10 
BCN-02 2.66 ± 0.23 2.54 ± 0.11 0.48 
Chloroquine 2.21 ± 0.50 1.25 ± 0.11 0.03 
7c 3.50 ± 2.38 1.37 ± 0.93 0.22 
7d 1.69 ± 0.42 2.04 ± 0.39 0.35 
Primaquine NA 3.93 ± 1.29 NA 
Tafenoquine NA 4.95 ± 3.32 NA 
Quinacrine 1.63 ± 0.27 1.31 ± 0.33 0.26 
 
  
14 
 
Table S2. Analysis of drug interaction with LPs during the citrate-buffered, pH gradient-based 
active encapsulation process for BCN-01, BCN-02, 7c and 7d. LP surface charge and size results 
were obtained from 500 µM/10 mM drug/lipid mixtures, expressed as mean ζ potential (mV) and 
diameter (nm), respectively, with the corresponding standard deviation from three individual 
measurements and determined before and after the buffer exchange (BE) step required for the 
removal of non-encapsulated contents. Because no differences in particle size and polydispersity 
index (PDI) were observed between control and drug-containing LPs, mean particle size and PDI 
are provided for each group of samples.  p values are included in the table comparing results from 
LP control vs. LP[drug] samples. 
 
  p values 
 
Mean ζ-potential (mV) ± SD LP[BCN-01] LP[BCN-02] LP[7c] LP[7d] 
 LPs in citrate (mean particle size: 203.9 ± 2.1 nm; PDI: 0.25 ± 0.02) 
LP -2.61 ± 0.20 2.39 × 10-6 9.92 × 10-10 2.98 × 10-10 7.25 × 10-5 
LP[BCN-01] 6.61 ± 0.24 - 8.31 × 10-4 5.23 × 10-4 3.86 × 10-6 
LP[BCN-02] 8.43 ± 0.15 - - 4.70 × 10-6 1.44 × 10-6 
LP[7c] 4.05 ± 0.12 - - - 7.07 × 10-5 
LP[7d] -0.12 ± 0.21 - - - - 
      
 LPs after BE (mean particle size: 177.4 ± 1.7 nm; PDI: 0.12 ± 0.03) 
LP -17.55 ± 1.18 0.56 0.81 0.64 0.78 
LP[BCN-01] -16.63 ± 2.20 - 0.64 0.69 0.65 
LP[BCN-02] -17.37 ± 0.96 - - 0.86 0.97 
LP[7c] -17.23 ± 0.76 - - - 0.89 
LP[7d] -17.33 ± 0.96 - - - - 
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Table S3. Determination of statistical differences in P. falciparum growth inhibition assays for the 
analysis of GPA-iLP[drug] antimalarial activity in vitro. Parasite growth in cultures of the CQ-
sensitive/resistant 3D7/W2mef strains at either ring (early) or late P. falciparum blood stages is 
expressed as log10(IC50, nM) ± standard deviation from at least three experimental replicates. 
Impaired t-test p values are included in the table comparing log10(IC50, nM) results from free drug 
vs. iLP[drug] culture conditions. 
 
 log10[IC50 (nM)] ± SD  
 
Free drug iLP[drug] p value 
Rings (3D7) 
BCN-02 3.01 ± 4.32 × 10-3 2.25 ± 1.92 × 10-3  <1 × 10-4 
7c 3.08 ± 0.07 1.84 ± 0.03 <1 × 10-4 
Chloroquine 2.24 ± 0.09 1.75 ± 0.02 9 × 10-4 
Quinacrine 2.04 ± 0.04  1.65 ± 0.03 <1 × 10-4 
    
 
Late forms (3D7) 
BCN-02 3.03 ± 0.03 2.29 ± 0.02 <1 × 10-4 
7c 3.07 ± 0.04 2.00 ± 3.06 × 10-3  <1 × 10-4 
Chloroquine 2.24 ± 0.09 1.71 ± 0.05 1 × 10-3 
Quinacrine 2.01 ± 0.02 1.65 ± 0.02 <1 × 10-4 
    
 Late forms (W2mef) 
7c 3.11 ± 0.05 1.69 ± 0.03 <1 × 10-4 
Chloroquine 3.38 ± 0.19 2.81 ± 4.12 × 10-3 0.01 
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Table S4. MTD assay of intraperitoneally administered BCN-02 formulated in a 10% v/v chloroform/RPMI-A emulsion and following a 4-day dosage 
regime. Toxicity results are expressed from individually treated mice as animal weight (g) along with the corresponding weight loss (%) on the day of 
study relative to the start of the assay (Day 0). The four days when drug was injected are indicated in bold. (*) Dead animal, weighted animal corpse. 
(**) Amount of chloroform corresponding to the 50 mg/kg dose administered of BCN-02. 
 
 
 Weight of mice (g) 
 
Day 0 Day 1 % Day 2 % Day 3 % Day 4 % Day 5 % Day 6 % Day 7 % Day 8 % 
Emulsified BCN-02 
50 mg/kg 18.50 17.95* -2.97 - - - - - - -  - - - - - - - 
20 mg/kg 20.13 19.33 -3.97 18.93* -5.98 - - - - - - - - - - - - 
10 mg/kg 18.60 17.87 -3.94 18.00 -3.23 18.03 -3.05 18.03 -3.05 18.32 -1.51 18.23 -1.99 18.25 -1.88 18.12 -2.58 
5 mg/kg 19.40 18.97 -2.23 19.40 0.00 19.40 0.00 19.10 -1.55 19.23 -0.88 19.12 -1.44 19.24 -0.82 19.13 -1.39 
1 mg/kg 18.43 18.03 -2.17 18.50 0.36 18.90 2.53 18.57 0.72 18.52 0.47 18.68 1.34 18.58 0.80 18.61 0.96 
0 mg/kg 19.03 18.67 -1.93 18.97 -0.35 19.07 0.18 18.57 -2.45 18.82 -1.12 19.02 -0.07 18.75 -1.49 18.69 -1.80 
 
                 
Chloroform/RPMI-A 10% v/v 
10% v/v ** 19.72 19.78 0.30 19.82 0.51 19.74 0.10 19.45 -1.37 19.57 -0.76 19.68 -0.20 19.35 -1.88 19.71 -0.05 
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Table S5. MTD assay of intravenously administered 7c and BCN-02 formulated in 10% v/v chloroform/RPMI-A emulsion. Individual mice were treated 
at day 0 with the indicated single doses. Toxicity is determined by animal weight (g) along with the corresponding weight loss (%) on the day of study 
relative to day 0. (†) Dead animal within the day of administration. (*) Significant loss in animal weight (>10%). (**) Dead animal, weighted animal 
corpse. 
 
 
Weight of mice (g) 
 
Day 0 Day 1 % Day 2 % Day 3 % 
Emulsified 7c 
10 mg/kg 20.62† - - - - - - 
5 mg/kg 20.23† - - - - - - 
2.5 mg/kg 21.41 19.22* -10.23 18.78** -12.28 - - 
1 mg/kg 20.82 19.25 -7.54 19.19 -7.83 18.56** -10.85 
0 mg/kg 21.04 21.08 0.19 20.98 -0.29 21.12 0.38 
 Emulsified BCN-02 
10 mg/kg 22.49† - - - - - - 
5 mg/kg 19.78† - - - - - - 
2.5 mg/kg 20.55 18.02** -12.31 - - - - 
1 mg/kg 21.25 19.56 -7.95 19.02* -10.49 18.89** -11.11 
0 mg/kg 20.91 21.15 1.15 21.24 1.58 21.11 0.96 
 Chloroform/RPMI-A 
10% v/v 21.44 19.95 -6.95 19.85 -7.42 19.53 -8.91 
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Table S6. MTD assay of passively encapsulated, non-targeted LP[7c] and LP[BCN-02] formulations, intravenously administered following a 4-day 
dosage regime. Toxicity results are expressed from individually treated mice as animal weight (g) along with the corresponding weight loss (%) on the 
day of study relative to the start of the assay (Day 0). The four days at which LP[drug] samples were injected are indicated in bold. (*) Significant loss 
in animal weight (>10%). (**) Dead animal, weighted animal corpse. 
 
 
 
 
 
 Weight of mice (g) 
 
Day 0 Day 1 % Day 2 % Day 3 % Day 4 % Day 5 % Day 6 % Day 7 % Day 8 % 
LP[7c] 
20 mg/kg 19.32 19.18 -0.72 19.60 1.45 19.31 -0.05 19.43 0.57 18.57 -3.88 19.02 -1.55 17.23 -10.82* 16.93** -12.37* 
10 mg/kg 22.25 22.13 -0.54 21.80 -2.02 22.30 0.22 21.76 -2.20 21.59 -2.97 22.19 -0.27 21.62 -2.83 21.7 -2.47 
5 mg/kg 24.79 25.28 1.98 24.30 -1.98 24.55 -0.97 24.53 -1.05 24.48 -1.25 24.56 -0.93 24.35 -1.77 24.25 -2.18 
1 mg/kg 23.42 23.80 1.62 23.05 -1.58 23.04 -1.62 23.37 -0.21 23.28 -0.60 23.52 0.43 23.05 -1.58 22.74 -2.90 
0 mg/kg 21.35 21.05 -1.41 21.30 -0.23 21.51 0.75 21.52 0.80 21.43 0.37 21.29 -0.28 21.36 0.05 20.76 -2.76 
                  
LP[BCN-02] 
20 mg/kg 21.05 20.95 -0.48 21.03 -0.10 21.12 0.33 21.07 0.10 20.95 -0.48 21.09 0.19 20.64 -1.95 20.54 -2.42 
10 mg/kg 21.26 21.30 0.19 21.20 -0.28 21.22 -0.19 21.13 -0.61 21.12 -0.66 21.24 -0.09 20.78 -2.26 20.82 -2.07 
5 mg/kg 21.12 21.07 -0.24 21.15 0.14 20.58 -2.56 20.19 -4.40 20.53 -2.79 21.08 -0.19 20.49 -2.98 20.62 -2.37 
1 mg/kg 21.01 20.85 -0.76 21.60 2.81 20.88 -0.62 20.72 -1.38 20.78 -1.09 21.12 0.52 21.28 1.29 21.05 0.19 
0 mg/kg 22.49 22.55 0.27 22.50 0.04 22.30 -0.84 22.80 1.38 22.42 -0.31 22.24 -1.11 21.96 -2.36 22.03 -2.05 
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Table S7. In vivo toxicity results obtained for the intravenously administered LP[7c] and TER119-
iLP[7c] actively-encapsulated antimalarial formulations from Fig. 6. Toxicity results are expressed 
as mean mouse weight (g) from at least three independent animal replicates along with the 
corresponding weight loss (%) on the day of study relative to the start of the assay (Day 0). The 
days at which LP[drug] samples were injected have been labeled in bold. 
 
 
Mice (n = 3) Day 0 Day 1 % Day 2 % Day 3 % 
iL
P
[7
c]
 M1 17.97 16.98 -5.51 16.91 -5.89 17.21 -4.24 
M2 15.62 15.30 -6.83 14.50 -7.18 14.75 -5.55 
M3 17.11 15.90 -7.07 15.87 -7.22 16.16 -5.56 
Mean 16.90 16.06 -6.47 15.76 -6.76 16.04 -5.12 
LP
[7
c]
 M1 17.97 18.21 1.34 17.90 -0.39 17.90 -0.39 
M2 15.07 15.51 2.92 15.30 1.53 15.30 1.53 
M3 17.81 18.14 1.85 17.50 -1.74 18.10 1.63 
Mean 16.95 17.29 2.04 16.90 -0.20 17.10 0.92 
U
nt
re
at
ed
 
M1 18.03 17.66 -2.05 17.20 -4.60 17.80 -1.28 
M2 16.70 17.40 4.19 17.10 2.40 17.40 4.19 
M3 15.84 16.78 5.93 16.80 6.06 16.50 4.17 
Mean 16.86 17.28 2.69 17.03 1.28 17.23 2.36 
 
 
 
